- Home
- HRMY vs FIVN Comparison
HRMY vs FIVN Comparison
Compare HRMY & FIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- FIVN
- Stock Information
- Founded
- HRMY 2017
- FIVN 2001
- Country
- HRMY United States
- FIVN United States
- Employees
- HRMY N/A
- FIVN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- FIVN EDP Services
- Sector
- HRMY Health Care
- FIVN Technology
- Exchange
- HRMY Nasdaq
- FIVN Nasdaq
- Market Cap
- HRMY 2.0B
- FIVN 2.3B
- IPO Year
- HRMY 2020
- FIVN 2014
- Fundamental
- Price
- HRMY $31.89
- FIVN $26.85
- Analyst Decision
- HRMY Strong Buy
- FIVN Buy
- Analyst Count
- HRMY 9
- FIVN 21
- Target Price
- HRMY $54.22
- FIVN $43.95
- AVG Volume (30 Days)
- HRMY 611.9K
- FIVN 1.7M
- Earning Date
- HRMY 08-05-2025
- FIVN 08-07-2025
- Dividend Yield
- HRMY N/A
- FIVN N/A
- EPS Growth
- HRMY 13.13
- FIVN N/A
- EPS
- HRMY 2.62
- FIVN N/A
- Revenue
- HRMY $744,852,000.00
- FIVN $1,074,633,000.00
- Revenue This Year
- HRMY $20.10
- FIVN $11.81
- Revenue Next Year
- HRMY $18.01
- FIVN $9.79
- P/E Ratio
- HRMY $12.17
- FIVN N/A
- Revenue Growth
- HRMY 20.62
- FIVN 14.44
- 52 Week Low
- HRMY $26.47
- FIVN $21.04
- 52 Week High
- HRMY $41.61
- FIVN $49.90
- Technical
- Relative Strength Index (RSI)
- HRMY 36.85
- FIVN 46.55
- Support Level
- HRMY $32.39
- FIVN $26.52
- Resistance Level
- HRMY $33.42
- FIVN $28.02
- Average True Range (ATR)
- HRMY 1.06
- FIVN 1.07
- MACD
- HRMY -0.47
- FIVN -0.20
- Stochastic Oscillator
- HRMY 6.91
- FIVN 27.66
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.